Prime Capital Investment Advisors LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 64.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 575 shares of the biopharmaceutical company’s stock after selling 1,034 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Pfizer were worth $25,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Thoroughbred Financial Services LLC raised its position in shares of Pfizer by 4,297.8% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock worth $265,668,000 after acquiring an additional 2,596,269 shares in the last quarter. Marshall Wace North America L.P. grew its stake in Pfizer by 52.9% during the 1st quarter. Marshall Wace North America L.P. now owns 7,431,974 shares of the biopharmaceutical company’s stock worth $315,635,000 after buying an additional 2,571,626 shares during the last quarter. California Public Employees Retirement System grew its stake in Pfizer by 14.0% during the 4th quarter. California Public Employees Retirement System now owns 20,333,138 shares of the biopharmaceutical company’s stock worth $887,541,000 after buying an additional 2,504,336 shares during the last quarter. Railway Pension Investments Ltd purchased a new position in Pfizer during the 2nd quarter worth $10,019,000. Finally, Fisher Asset Management LLC grew its stake in Pfizer by 3.7% during the 2nd quarter. Fisher Asset Management LLC now owns 44,133,251 shares of the biopharmaceutical company’s stock worth $1,911,852,000 after buying an additional 1,559,405 shares during the last quarter. 71.58% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Frank A. Damelio sold 153,184 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total value of $6,753,882.56. Following the sale, the executive vice president now owns 489,647 shares in the company, valued at $21,588,536.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Alexander R. Mackenzie sold 30,000 shares of the company’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $44.00, for a total value of $1,320,000.00. Following the completion of the sale, the insider now owns 80,094 shares in the company, valued at approximately $3,524,136. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. The business had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.77 EPS. Research analysts forecast that Pfizer Inc. will post 2.8 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be paid a dividend of $0.36 per share. The ex-dividend date is Thursday, August 1st. This represents a $1.44 annualized dividend and a yield of 4.19%. Pfizer’s payout ratio is presently 48.00%.
Several research analysts recently weighed in on PFE shares. Bank of America downgraded Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. Barclays restated a “hold” rating and set a $41.00 target price on shares of Pfizer in a research note on Thursday, May 9th. UBS Group restated a “neutral” rating and set a $43.00 target price on shares of Pfizer in a research note on Monday, August 5th. Credit Suisse Group restated a “neutral” rating on shares of Pfizer in a research note on Monday, August 12th. Finally, Morgan Stanley downgraded Pfizer from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $48.00 to $40.00 in a research note on Tuesday, July 30th. Fourteen equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus price target of $46.67.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: What are benefits of a growth and income fund?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.